Alnylam Pharmaceuticals, Inc.
General ticker "ALNY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $32.1B
Alnylam Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 45.3%.
Estimated limits based on current volatility of 1.9%: low 235.55$, high 244.80$
Factors to consider:
- US accounted for 44.3% of revenue in the fiscal year ended 2022-12-31
- Current price 16.4% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [108.23$, 209.07$]
- 2024-12-30 to 2025-12-30 estimated range: [87.00$, 173.63$]
Financial Metrics affecting the ALNY estimates:
- Negative: Non-GAAP EPS, $ of -3.56 <= 0.10
- Negative: Operating profit margin, % of -13.37 <= 1.03
- Positive: -3.48 < Investing cash flow per share, $ of -2.69
- Negative: Operating cash flow per share per price, % of 0.47 <= 2.35
- Negative: negative Net income
Short-term ALNY quotes
Long-term ALNY plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $844.29MM | $1,037.42MM | $1,828.29MM |
| Operating Expenses | $1,552.94MM | $1,822.49MM | $2,110.47MM |
| Operating Income | $-708.65MM | $-785.07MM | $-282.18MM |
| Non-Operating Income | $-143.49MM | $-341.92MM | $-151.34MM |
| Interest Expense | $143.02MM | $155.97MM | $121.22MM |
| R&D Expense | $792.16MM | $883.01MM | $1,004.41MM |
| Income(Loss) | $-852.14MM | $-1,126.99MM | $-433.52MM |
| Taxes | $0.68MM | $4.16MM | $6.72MM |
| Profit(Loss) | $-852.82MM | $-1,131.16MM | $-440.24MM |
| Stockholders Equity | $588.20MM | $-158.22MM | $-220.64MM |
| Inventory | $122.70MM | $128.96MM | $89.15MM |
| Assets | $3,643.30MM | $3,546.36MM | $3,829.88MM |
| Operating Cash Flow | $-641.69MM | $-541.27MM | $104.16MM |
| Capital expenditure | $76.37MM | $72.06MM | $62.21MM |
| Investing Cash Flow | $-273.30MM | $169.35MM | $-336.35MM |
| Financing Cash Flow | $1,247.12MM | $425.75MM | $172.13MM |
| Earnings Per Share* | $-7.20 | $-9.30 | $-3.52 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.